bismuth subsalicylate (Pepto-bismol)

bismuth subsalicylate is the active ingredient of Pepto-Bismol and in Kaopectate; used to treat nausea, heartburn, indigestion, upset stomach, diarrhea and other temporary discomforts of the stomach; used with Azoles and other drugs to treat Helicobacter

Also Known As:

Networked: 153 relevant articles (34 outcomes, 28 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Chande, N: 8 articles (01/2008 - 01/2002)
2.	McDonald, J W D: 6 articles (01/2008 - 01/2003)
3.	MacDonald, J K: 5 articles (01/2006 - 01/2002)
4.	Macdonald, J K: 3 articles (01/2008 - 01/2005)
5.	Prapitpaiboon, Hatainuch: 2 articles (01/2015 - 01/2015)
6.	Mahachai, Varocha: 2 articles (01/2015 - 01/2015)
7.	Uygun, Ahmet: 2 articles (02/2012 - 11/2007)
8.	Kadayifci, Abdurrahman: 2 articles (02/2012 - 11/2007)
9.	Food and Drug Administration, HHS: 2 articles (05/2004 - 04/2003)
10.	McDonald, J W: 2 articles (01/2003 - 01/2002)

Related Diseases

1.	Diarrhea 09/01/1990 - "Bismuth subsalicylate has shown modest efficacy in treating traveler's diarrhea and acute and chronic diarrhea in children, and it is effective prophylactically for traveler's diarrhea. " 11/01/1977 - "Preparations containing bismuth subsalicylate may be effective in the prevention of diarrhea mediated by toxigenic E. " 12/01/2005 - "Among the nonantimicrobial agents that are available and useful for the treatment of traveler's diarrhea are bismuth subsalicylate-containing preparations, which reduce the passage of loose stools by 16%-18%. " 01/01/1990 - "Several studies have documented the efficacy of bismuth subsalicylate (BSS) for the prophylaxis and treatment of bacterial diarrhea. " 05/01/1988 - "The goals of this study were threefold: to compare the etiology of travelers' diarrhea in West Africa and Mexico, to evaluate two fecal transport systems for the recovery of enteropathogens, and to verify the efficacy of liquid bismuth subsalicylate (BSS) in different locations and under different entrance criteria for disease severity. "
2.	Infection 12/01/1990 - "infection was apparently eliminated in 50% of cases treated with bismuth subsalicylate (BSS) for four weeks. " 10/01/2014 - "The study population consisted of 54 patients with Helicobacter pylori infection: 29 were allocated to the experimental group, who received the usual triple plus bismuth subsalicylate therapy, and 24 received the triple therapy plus placebo. " 10/01/2014 - "To establish the efficiency and adverse effects of the addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection. " 10/01/2014 - "[Addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection: efficiency and adverse events]." 06/01/2001 - "Which place for bismuth subsalicylate in the treatment of enteric infections?"
3.	Gastritis 06/10/1988 - "These results demonstrate that bismuth subsalicylate is highly effective in the acute treatment of CP-associated chronic erosive gastritis." 09/01/1989 - "The effect of bismuth subsalicylate on the histologic gastritis seen with Campylobacter pylori: a placebo-controlled, randomized study." 06/10/1988 - "In a prospective open study 21 patients with upper abdominal complaints and chronic active gastritis as well as endoscopically proven erosions were treated with bismuth subsalicylate (4 X 30 ml/day, corresponding to 4 X 314 mg Bi3+) for three weeks. " 01/01/1990 - "Bismuth subsalicylate in the treatment of gastritis due to Campylobacter pylori." 06/10/1988 - "[Bismuth subsalicylate treatment in chronic Campylobacter pylori-associated erosive gastritis]."
4.	Collagenous Colitis 07/01/2000 - "Collagenous colitis treated successfully with bismuth subsalicylate." 01/01/2009 - "Bismuth subsalicylate was reported to be effective in a small controlled series of patients with collagenous colitis. " 01/01/2007 - "A single randomized trial published in abstract form only which studied bismuth subsalicylate was identified, and included only 5 patients with lymphocytic colitis (and 9 with collagenous colitis). " 01/01/2008 - "In treating active disease, there were 9 patients with collagenous colitis in the trial studying bismuth subsalicylate (nine 262 mg tablets daily for 8 weeks). " 01/01/2006 - "There were 9 patients with collagenous colitis in the trial studying bismuth subsalicylate (nine 262 mg tablets daily for 8 weeks). "
5.	Dyspepsia (Indigestion) 02/01/1984 - "The efficacy of bismuth subsalicylate in relieving the symptoms of indigestion was evaluated in a randomized, placebo-controlled, double-blind, cross-over study in 48 adults. " 09/01/1993 - "Bismuth subsalicylate suppression of Helicobacter pylori in nonulcer dyspepsia: a double-blind placebo-controlled trial." 02/01/1984 - "Each patient was treated for six episodes of indigestion, three episodes with bismuth subsalicylate and three with placebo. " 02/01/1984 - "Evaluation of bismuth subsalicylate in relieving symptoms of indigestion." 05/01/1998 - "The mechanism by which dietary pepper causes dyspepsia and epigastric pain is poorly understood, as is the ability of bismuth subsalicylate (BSS) to relieve these symptoms. "

Related Drugs and Biologics

1.	bismuth subsalicylate (Pepto-bismol)
2.	Tablets
3.	Metronidazole (Metric)
4.	Amoxicillin (Wymox)
5.	Antral
6.	bismuth tripotassium dicitrate (bismuth subcitrate)
7.	Nitrofurantoin (Macrodantin)
8.	Loperamide (Imodium)
9.	Mesalamine (Mesalazine)
10.	Cholestyramine Resin (Questran)

Related Therapies and Procedures

1.	Enema (Enemas)
2.	Fluid Therapy (Oral Rehydration Therapy)
3.	Aftercare (After-Treatment)
4.	Tracheostomy